Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedicitumab + carboplatin + toripalimab for HER2-expressing advanced or recurrent endometrial cancer
ChiCTR2400093881Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Dec 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin, carboplatin and toripalimab in endometrial cancer (EC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: progression-free survival. Started Dec 2024; status: recruiting.
02
Drugs
disitamab vedotincarboplatintoripalimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2400093881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093881.